| Technical Name | DBPR112: EGFR Kinase Inhibitor | ||
|---|---|---|---|
| Project Operator | National Health Research Institutes | ||
| Project Host | - | ||
| Summary | DBPR112 is a potent EGFR-TKI, which is potentially better than afatinib (developed by Boehringer Ingelheim,approved by FDA in 2013). DBPR112 was orally effective against the growth of human xenografts employing cells derived from lung, headneck, breast,esophageal cancers. The pharmacokinetics properties of DBPR112 are superior to those of afatinib demonstrating the potential of DBP |
||
| Scientific Breakthrough | - |
||
| Industrial Applicability | - |
||
| Keyword | |||
- futuretech.most@gmail.com
other people also saw